参考文献/References:
[1] Institute for Quality and Efficiency in Health Care. Positron emission tomography (PET) and PET/CT for recurrence diagnosis in high-grade malignant glioma (grades III and IV):Executive summary of final report D06-01D, Version 1.0[EB/OL].[2013-05-26]. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033979.
[2] G?tz L, Spehl TS, Weber WA, et al. PET and SPECT for radiation treatment planning. Q J Nucl Med Mol Imaging, 2012, 56(2):163-172.
[3] 徐高峰,白晓斌,王茂德,等.脑胶质瘤细胞糖酵解表型特征及对细胞增殖与凋亡的影响.南方医科大学学报,2013, 33(3):406-411.
[4] Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor:a systematic review and Metaanalysis. J Nucl Med, 2012,53(2):207-214.
[5] Li DL, Xu YK, Wang QS, et al. 13C-methionine and 18F-fluo-rodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J (Engl), 2012, 125(1):91-96.
[6] Tripathi M, Sharma R, D’Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med, 2009, 34(12):878-883,
[7] Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy:a comprehensive review. Expert Rev Neurother, 2013, 13(4):389-403.
[8] Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with[13C]L-methionine positron emission tomography:local comparison with stereotactic histopathology. Clin Cancer Res, 2004,10(21):7163-7170.
[9] Kato T, Shinoda J, Nakayama N, et al. Metabolic assessment of gliomas using 13C-methionineT[18F]fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol, 2008,29(6):1176-1182.
[10] Crippa F, Alessi A, Serafini GL. PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging, 2012, 56(2):151-162.
[11] Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging, 2012, 56(2):173-190.
[12] Miyake K, Shinomiya A, Okada M, et al. Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas[J/OL]. J Biomed Biotechnol, 2012, 2012[2013-05-26], http://www.hin-dawi.com/joumals/bmri/2012/205818.
[13] Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET:comparison with 18F-FDG. J Nucl Med, 2005,46(6):945-952.
[14] Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol, 2011, 13(3):307-316.
[15] Fueger BJ, Czemin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med, 2010, 51(10):1532-1538.
[16] Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors:comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med, 2006,47(6):904-911.
[17] Chierichetti F, Pizzolato G. 18F-FDG-PET/GT. Q J Nucl Med Mol Imaging, 2012, 56(2):138-150.
[18] Yang S, Zhang C, Zhu T, et al. Resection of gliomas using positron emission tomography/computed tomography neuronavigation. Neurol Med Chir(Tokyo), 2007,47(9):397-401,402.
[19] Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med, 2004,45(8):1293-1298.
[20] Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med, 2005, 46(12):1948-1958.
[21] Ceyssens S, Van Laere K, de Groot T, et al.[11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol, 2006, 27(7):1432-1437.
[22] Munck Af Rosenschold P, Engelholm S, Ohlhues L, et al. Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncol, 2011, 50(6):777-783.
[23] Li FM, Nie Q, Wang RM, et al. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas. Nucl Med Biol, 2012, 39(3):437-442.
[24] Gramatzki D, Herrmann C, Happold C, et al. Glioma cell death induced by inadiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway[J/OL]. PLoS One, 2013, 8(5):e63527[2013-05-26]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjoumal.pone.0063527.
[25] Enslow MS, Zollinger LV, Morton KA, et al. Comparison of 18F-fluo-rodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med, 2012, 37(9):854-861.
[26] Santra A, Kumar R, Sharma P, et al. F-18 FDG PET-CT in patients with recurrent glioma:comparison with contrast enhanced MRI. EurJ Radiol, 2012, 81(3):508-513.
[27] Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med, 2000, 41(11):1861-1867.
[28] Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med, 2008, 49(5):694-699.
[29] Tripathi M, Sharma R, Varshney R, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med, 2012, 37(2):158-163.
[30] Lam WW, Ng DC, Wong WY, et al. Promising role of[18F] fluoro-choline PET/CT vs[18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin Neurol Neurosurg, 2011, 113(2):156-161.
[31] Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA, 2013, 110(21):8644-8649.
[32] Walter F, Cloughesy T, Walter MA, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors:the referring physician’s perspective. J Nucl Med, 2012,53(3):393-398.
[33] Santra A, Kumar R, Sharma P, et al. F-18 FDG PET-CT for predicting survival in patients with recurrent glioma:a prospective study. Neuroradiology, 2011,53(12):1017-1024.
[34] Cheimley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolo-mide plus radiotherapy. Int J Radiat Oncol Biol Phys, 2006, 66(2):331-338.
[35] Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med, 2011, 52(6):856-864.
[36] González-Forero M, Prieto E, Dominguez I, et al. Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors. Rev Esp Med Nucl, 2011,30(2):88-93.
相似文献/References:
[1]程勇军,赵晋华.东亚钳蝎氯毒素在胶质瘤靶向显像与治疗中的研究进展[J].国际放射医学核医学杂志,2015,39(1):32.[doi:10.3760/cma.j.issn.1673-4114.2015.01.008]
Cheng Yongjun,Zhao Jinhua.Development of research in targeting image and therapy of gliomas using Buthus martensii Karsch chlorotoxin[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):32.[doi:10.3760/cma.j.issn.1673-4114.2015.01.008]
[2]高艳,赵晋华.PET/MRI融合显像在脑胶质瘤诊断和治疗中的研究进展[J].国际放射医学核医学杂志,2015,39(1):71.[doi:10.3760/cma.j.issn.1673-4114.2015.01.015]
Gao Yan,Zhao Jinhua.The advancement of PET/MRI on the diagnosis and treatment of brain gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):71.[doi:10.3760/cma.j.issn.1673-4114.2015.01.015]
[3]张华,姚振威.细胞示踪影像学技术的发展[J].国际放射医学核医学杂志,2015,39(2):180.[doi:10.3760/cma.j.issn.1673-4114.2015.02.017]
Zhang Hua,Yao Zhenwei.The development of cell tracking technology[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):180.[doi:10.3760/cma.j.issn.1673-4114.2015.02.017]
[4]周新韩,高明勇,张仙海,等.磁敏感加权成像显示肿瘤内静脉评价胶质瘤分级[J].国际放射医学核医学杂志,2014,38(6):373.[doi:10.3760/cma.j.issn.1673-4114.2014.06.006]
Zhou Xin-han,Gao Ming-yong,Zhang Xian-hai,et al.Values of tumor vein detected by susceptibility weighted imaging in evaluation of gliomas grade[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):373.[doi:10.3760/cma.j.issn.1673-4114.2014.06.006]
[5]郁春景,吴翼伟,万卫星.P-gp功能的PET显像剂的研究进展[J].国际放射医学核医学杂志,2014,38(6):403.[doi:10.3760/cma.j.issn.1673-4114.2014.06.013]
Yu Chun-jing,Wu Yi-wei,Wan Wei-xing.Progress in PET imaging evaluating of P-gp function[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):403.[doi:10.3760/cma.j.issn.1673-4114.2014.06.013]
[6]李平,宗天舟,季晓芹,等.CD133+U87人脑胶质瘤干细胞放射敏感性和DNA双链断裂损伤修复的实验研究[J].国际放射医学核医学杂志,2013,37(3):153.[doi:10.3760/cma.j.issn.1673-4114.2013.03.007]
LI Ping,ZONG Tian-zhou,JI Xiao-qin,et al.CD133 positive U87 glioma stem cell radiosensitivity and DNA double-strand break repair[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):153.[doi:10.3760/cma.j.issn.1673-4114.2013.03.007]
[7]展凤麟,汪世存,潘博,等.11C-胆碱和18F-FDG PET/CT显像在脑胶质瘤诊断中的应用[J].国际放射医学核医学杂志,2013,37(4):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
ZHAN Feng-lin,WANG Shi-cun,PAN Bo,et al.Application of 11C-choline and 18F-FDG PET/CT in diagnosing brain glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
[8]杨辉,张富强,李文亮,等.术中125Ⅰ粒子植入治疗复发性脑胶质瘤的临床研究[J].国际放射医学核医学杂志,2013,37(6):345.[doi:10.3760/cma.j.issn.1673-4114.2013.06.005]
YANG Hui,ZHANG Fu-qiang,LI Wen-liang,et al.Clinical study of operation combined with 125Ⅰ seeds implantation in the treatment of recurrent cerebral glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):345.[doi:10.3760/cma.j.issn.1673-4114.2013.06.005]
[9]刘金剑,刘鉴峰,孟爱民.噬菌体展示技术在分子核医学中的应用[J].国际放射医学核医学杂志,2013,37(6):352.[doi:10.3760/cma.j.issn.1673-4114.2013.06.007]
LIU Jin-jian,LIU Jian-feng,MENG Ai-min.Application of phage display technique in molecular nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):352.[doi:10.3760/cma.j.issn.1673-4114.2013.06.007]
[10]刁焕荣,刘晓岚.MRI在颅内恶性胶质瘤放疗中的应用进展[J].国际放射医学核医学杂志,2011,35(3):185.[doi:10.3760/cma.j.issn.1673-4114.2011.03.013]
DIAO Huan-rong,LIU Xiao-lan.The use of MRI in radiotherapy of brain malignant gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):185.[doi:10.3760/cma.j.issn.1673-4114.2011.03.013]
[11]周惠君,董萍,沈国华,等.11C-蛋氨酸PET/CT显像在脑胶质瘤中的应用价值[J].国际放射医学核医学杂志,2015,39(2):161.[doi:10.3760/cma.j.issn.1673-4114.2015.02.013]
Zhou Huijun,Dong Ping,Shen Guohua,et al.Value of 11C-methionine PET/CT imaging indiagnosing cerebral glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):161.[doi:10.3760/cma.j.issn.1673-4114.2015.02.013]
[12]孙娜,赵晋华,乔文礼.胶质瘤显像剂的研究与应用进展[J].国际放射医学核医学杂志,2011,35(6):330.[doi:10.3760,cma.j.issn.1673-4114.2011.06.003]
SUN Na,ZHAO Jin-hua,QIAO Wen-li.Advances in appUcafion of radiotracers for glioma imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):330.[doi:10.3760,cma.j.issn.1673-4114.2011.06.003]